• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Dyne Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    6/30/25 4:01:19 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DYN alert in real time by email
    8-K
    false 0001818794 0001818794 2025-06-27 2025-06-27
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of report (Date of earliest event reported): June 27, 2025

     

     

    Dyne Therapeutics, Inc.

    (Exact Name of Registrant as Specified in Charter)

     

     

     

    Delaware   001-39509   36-4883909

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    1560 Trapelo Road  
    Waltham, Massachusetts   02451
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s telephone number, including area code: (781) 786-8230

    Not applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    symbol(s)

     

    Name of each exchange

    on which registered

    Common stock, $0.0001 par value per share   DYN   Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 1.01

    Entry into a Material Definitive Agreement.

    On June 27, 2025 (the “Closing Date”), Dyne Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with Hercules Capital, Inc. (“Hercules”), in its capacity as administrative agent and collateral agent (the “Agent”) and as a lender, and certain other financial institutions that from time to time become parties to the Loan Agreement as lenders (collectively, the “Lenders”). The Loan Agreement provides for term loans in an aggregate principal amount of up to $275.0 million under multiple tranches (the “Term Loans”), available as follows: (i) an initial term loan tranche funded on the Closing Date in aggregate principal amount of $100.0 million (the “Initial Tranche”); (ii) subject to the achievement of specified clinical, regulatory and commercial milestones, three additional term loan tranches totaling up to $115.0 million; and (iii) subject to approval by the Lenders’ investment committee in their discretion, a final term loan tranche of up to $60.0 million.

    All unpaid principal and accrued and unpaid interest with respect to the Term Loans is due and payable in full on July 1, 2030 (the “Maturity Date”). The outstanding principal balance of the Term Loans bears interest at a floating interest rate per annum equal to the Wall Street Journal prime rate, subject to a floor of 7.50%, plus 2.45%. Accrued interest on the outstanding Term Loans is payable monthly. The Company may make payments of interest only until July 1, 2028, which interest only period may be extended until the Maturity Date upon the achievement of specified clinical, regulatory and commercial milestones. At the end of the interest only period, the Company is required to begin repayment of the outstanding principal of the Term Loans in equal monthly installments (or, in a single installment, if the interest-only period has been extended to the Maturity Date).

    As collateral for the obligations under the Loan Agreement, the Company has granted to the Agent, for the benefit of the Lenders, a first-priority security interest in substantially all of its property, inclusive of intellectual property, subject to customary permitted liens and other exceptions set forth in the Loan Agreement.

    The Loan Agreement contains customary representations and warranties, events of default and affirmative and negative covenants, including a minimum cash covenant (the “Minimum Cash Covenant”) requiring the Company to maintain specified levels of cash in accounts subject to a control agreement in favor of the Agent (“Qualified Cash”) during the period commencing on April 1, 2026 (or January 1, 2027 if the Company has raised at least $350.0 million of cumulative net cash proceeds between June 4, 2025 and December 15, 2026 from the issuance of equity or indebtedness or payments under certain royalty or license transactions). The Minimum Cash Covenant will initially be set at 60% of the then outstanding principal balance of the Term Loans, is subject to adjustment and will not be tested at any time when the Company’s market capitalization is greater than $1.65 billion. The Company is also required to maintain minimum net product revenue from the sale of DYNE-101 and DYNE-251 starting nine months after U.S. Food and Drug Administration approval of DYNE-101 or DYNE-251 (the “Minimum Revenue Covenant”) if the outstanding principal balance of the Term Loans exceed $100.0 million. The Minimum Revenue Covenant will not be tested for any month to the extent that for each day during such month either (i) Qualified Cash is at least 100% of the Company’s outstanding obligations under the Loan Agreement or (ii) the Company’s market capitalization is greater than $1.65 billion and Qualified Cash is at least 50% of the Company’ outstanding obligations under the Loan Agreement. Certain negative covenants under the Loan Agreement limit the ability of the Company, among other things, to incur future debt, grant liens, make investments, make acquisitions, distribute dividends and sell assets, subject in each case to certain exceptions.

    Upon the occurrence of an event of default, including the failure by the Company to comply with the covenants under the Loan Agreement or the occurrence of a material adverse effect on the business, operations, properties, assets or financial condition of the Company, in each case subject to certain exceptions, and subject to any specified cure periods, all amounts owed by the Company under the Loan Agreement may be declared immediately due and payable by the Agent, and the Agent may foreclose on collateral.


    The Loan Agreement requires the Company to pay closing fees, prepayment penalties and an end-of-term charge equal to 5.5% of the amount of Term Loans borrowed, which amount is due at the earlier of prepayment or the Maturity Date. A prepayment penalty applies to any prepayment of the Term Loans prior to the Maturity Date equal to (i) 2.0% of the principal amount prepaid if the prepayment occurs on or prior to the first anniversary of the Closing Date, (ii) 1.5% of the principal amount prepaid if the prepayment occurs after the first anniversary and on or prior to the second anniversary of the Closing Date, and (iii) 0.75% of the principal amount prepaid if the prepayment occurs after the second anniversary through the day before the Maturity Date.

    The foregoing description of the Loan Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the Loan Agreement, a copy of which is filed as Exhibit 10.1, and incorporated herein by reference.

     

    Item 2.03

    Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

    The information set forth in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference herein.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits:

     

    Exhibit

    Number

      

    Description

    10.1+    Loan and Security Agreement, dated as of June 27, 2025, by and among the Company, Hercules Capital Inc., in its capacity as administrative agent and collateral agent for the lenders, and the lenders party thereto.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    +

    Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        DYNE THERAPEUTICS, INC.
    Date: June 30, 2025     By:  

    /s/ John G. Cox

        Name:   John G. Cox
        Title:   President and Chief Executive Officer
    Get the next $DYN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DYN

    DatePrice TargetRatingAnalyst
    6/24/2025$13.00Mkt Perform
    Bernstein
    6/11/2025$37.00Outperform
    Raymond James
    6/2/2025$34.00Outperform
    Oppenheimer
    5/29/2025$46.00Outperform
    Evercore ISI
    3/12/2025$50.00Outperform
    BMO Capital Markets
    3/7/2025$50.00Sector Outperform
    Scotiabank
    12/13/2024$46.00Outperform
    Robert W. Baird
    11/26/2024$45.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $DYN
    SEC Filings

    See more
    • SEC Form 424B5 filed by Dyne Therapeutics Inc.

      424B5 - Dyne Therapeutics, Inc. (0001818794) (Filer)

      7/1/25 4:49:58 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Dyne Therapeutics Inc.

      8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)

      7/1/25 4:40:23 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Dyne Therapeutics Inc.

      424B5 - Dyne Therapeutics, Inc. (0001818794) (Filer)

      6/30/25 4:43:07 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DYN
    Financials

    Live finance-specific insights

    See more
    • Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

      - Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase 1/2 ACHIEVE trial support vHOT as early indicator of clinical benefit with DYNE-101 in DM1 - - Ongoing Registrational Expansion Cohort in ACHIEVE trial to enroll 60 participants and include sites in U.S. - - Company to host an investor and analyst conference call today, June 17, at 8:00 a.m. ET - WALTHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically

      6/17/25 7:00:00 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET

      WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to provide an update on DYNE-101 in myotonic dystrophy type 1 (DM1) tomorrow, June 17, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and Webcast The live webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne's website, and a replay will be accessible for 90 days followin

      6/16/25 4:05:00 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

      - DYNE-101 in DM1: Dyne plans to initiate global Registrational Expansion Cohort of ACHIEVE trial with registrational dose of 6.8 mg/kg Q8W following study data showing splicing correction and robust and sustained functional improvements; potential to support H1 2026 submission for U.S. Accelerated Approval - - DYNE-251 in Exon 51 DMD: Based on recent FDA feedback, pursuing U.S. Accelerated Approval with dystrophin as surrogate endpoint; data from ongoing Registrational Expansion Cohort in DELIVER trial expected late 2025 with potential to support early 2026 regulatory submission - - Investor event today, January 10th at 8:00 a.m. ET - WALTHAM, Mass., Jan. 10, 2025 (GLOBE NE

      1/10/25 6:30:00 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DYN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO & President Cox John gifted 40,000 shares and bought $911,000 worth of shares (100,000 units at $9.11), increasing direct ownership by 42% to 202,179 units (SEC Form 4)

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      7/15/25 5:11:40 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO & President Cox John bought $1,057,216 worth of shares (32,000 units at $33.04) (SEC Form 4)

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      9/4/24 5:42:18 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kersten Dirk bought $29,999,988 worth of shares (1,714,285 units at $17.50) (SEC Form 4)

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      1/11/24 4:31:55 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DYN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer

      Brings a successful track record in clinical development and regulatory approval of innovative neuromuscular therapies Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases, today announced the appointment of Wildon Farwell, M.D., MPH, as chief medical officer ("CMO"). Dr. Farwell joins Satellos from Dyne Therapeutics (NASDAQ:DYN), where he most recently served as CMO and medical advisor. "We are thrilled to welcome Dr. Farwell as our CMO," said Frank Gleeson, Satellos co-founder and CEO. "He brings deep expertise in global clinical development — p

      7/16/25 7:00:00 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

      WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced underwritten public offering of 27,878,788 shares of its common stock at a public offering price of $8.25 per share, which includes 3,636,363 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds to Dyne from the offering were approximately $230.0 million, before deducting underwriting discounts and commissions a

      7/2/25 4:01:00 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock

      WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an underwritten public offering of 24,242,425 shares of its common stock at a public offering price of $8.25 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $200.0 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about July 2, 2025, subject to customary closing conditi

      6/30/25 9:45:00 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DYN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bernstein initiated coverage on Dyne Therapeutics with a new price target

      Bernstein initiated coverage of Dyne Therapeutics with a rating of Mkt Perform and set a new price target of $13.00

      6/24/25 8:00:58 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James resumed coverage on Dyne Therapeutics with a new price target

      Raymond James resumed coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $37.00

      6/11/25 7:53:49 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Dyne Therapeutics with a new price target

      Oppenheimer resumed coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $34.00

      6/2/25 8:51:54 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DYN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Commercial Officer Friedl-Naderer Johanna

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      7/18/25 5:21:09 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Kerr Douglas

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      7/18/25 5:20:39 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CEO & President Cox John

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      7/18/25 5:19:53 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DYN
    Leadership Updates

    Live Leadership Updates

    See more
    • Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer

      Brings a successful track record in clinical development and regulatory approval of innovative neuromuscular therapies Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases, today announced the appointment of Wildon Farwell, M.D., MPH, as chief medical officer ("CMO"). Dr. Farwell joins Satellos from Dyne Therapeutics (NASDAQ:DYN), where he most recently served as CMO and medical advisor. "We are thrilled to welcome Dr. Farwell as our CMO," said Frank Gleeson, Satellos co-founder and CEO. "He brings deep expertise in global clinical development — p

      7/16/25 7:00:00 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dyne Therapeutics Announces CEO Transition

      - John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO - WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of John Cox as president, chief executive officer (CEO) and a member of the Board of Directors, effective immediately. He succeeds Joshua Brumm, who has chosen to step down from these roles to pursue a career in healthcare investing. Mr. Brumm will serve as an advisor to Dyne to help ensure a seamles

      3/25/24 7:30:00 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development

      - Appointment Expands Dyne's Development Team as Company Advances Multiple Programs into Clinical Trials - WALTHAM, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of Francesco Bibbiani, M.D., as senior vice president, head of development. Dr. Bibbiani brings more than two decades of experience across development, including a focus on rare neuromuscular diseases as well as Duchenne muscular dystrophy (DMD). "We are excited to welcome Francesco to Dyne's development

      8/29/22 7:30:00 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DYN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

      SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)

      11/14/24 5:46:12 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

      SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)

      11/14/24 4:32:40 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

      SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)

      11/14/24 4:23:11 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care